Isoxicam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Isoxicam
Accession Number
DB08942
Type
Small Molecule
Groups
Withdrawn
Description

Isoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.

Structure
Thumb
Synonyms
Not Available
External IDs
W 8495
International/Other Brands
Maxicam
Categories
UNII
8XU734C4NG
CAS number
34552-84-6
Weight
Average: 335.335
Monoisotopic: 335.057591231
Chemical Formula
C14H13N3O5S
InChI Key
YYUAYBYLJSNDCX-UHFFFAOYSA-N
InChI
InChI=1S/C14H13N3O5S/c1-8-7-11(16-22-8)15-14(19)12-13(18)9-5-3-4-6-10(9)23(20,21)17(12)2/h3-7,18H,1-2H3,(H,15,16,19)
IUPAC Name
4-hydroxy-2-methyl-N-(5-methyl-2,3-dihydro-1,2-oxazol-3-ylidene)-1,1-dioxo-2H-1λ⁶,2-benzothiazine-3-carboxamide
SMILES
CN1C(C(=O)N=C2NOC(C)=C2)=C(O)C2=CC=CC=C2S1(=O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Isoxicam.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Isoxicam is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Isoxicam is combined with 5-androstenedione.Experimental, Illicit
AbciximabIsoxicam may increase the anticoagulant activities of Abciximab.Approved
AcebutololIsoxicam may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolIsoxicam may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Isoxicam.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alendronic acid.Approved
AliskirenIsoxicam may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Alminoprofen.Experimental
AlprenololIsoxicam may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Isoxicam.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Amcinonide.Approved
AmikacinThe risk or severity of nephrotoxicity can be increased when Isoxicam is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideIsoxicam may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Aminosalicylic Acid.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Isoxicam.Approved
AncrodIsoxicam may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Isoxicam.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Isoxicam is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Isoxicam is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Antipyrine.Approved, Investigational
Antithrombin III humanIsoxicam may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Antrafenine.Approved
ApixabanIsoxicam may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Isoxicam is combined with Apocynin.Investigational
ApramycinIsoxicam may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Isoxicam.Approved, Investigational
ArbekacinIsoxicam may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinIsoxicam may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIsoxicam may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololIsoxicam may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineIsoxicam may decrease the antihypertensive activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Atamestane.Investigational
AtenololIsoxicam may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Isoxicam.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Isoxicam.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Isoxicam is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Isoxicam.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Isoxicam.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Isoxicam is combined with Bacitracin.Approved, Vet Approved
BalsalazideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Balsalazide.Approved, Investigational
BecaplerminIsoxicam may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of gastrointestinal irritation can be increased when Beclomethasone dipropionate is combined with Isoxicam.Approved, Investigational
BefunololIsoxicam may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinIsoxicam may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Isoxicam.Approved
BenorilateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Isoxicam.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Isoxicam.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Benzydamine.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Isoxicam.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Isoxicam.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Betamethasone.Approved, Vet Approved
BetaxololIsoxicam may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Isoxicam.Approved, Investigational
BevantololIsoxicam may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Isoxicam.Approved, Investigational
BisoprololIsoxicam may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinIsoxicam may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololIsoxicam may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bucillamine.Investigational
BucindololIsoxicam may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of gastrointestinal irritation can be increased when Budesonide is combined with Isoxicam.Approved
BufexamacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bufexamac.Approved, Experimental
BufuralolIsoxicam may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Isoxicam.Approved
BupranololIsoxicam may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Isoxicam.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Isoxicam.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Isoxicam is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Isoxicam.Approved
CarprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololIsoxicam may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolIsoxicam may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Isoxicam.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Celecoxib.Approved, Investigational
CeliprololIsoxicam may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinIsoxicam may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Isoxicam.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Isoxicam.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Isoxicam.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cimicoxib.Investigational
CinoxacinIsoxicam may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinIsoxicam may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Isoxicam.Vet Approved
CloranololIsoxicam may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Isoxicam resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Isoxicam is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Isoxicam.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Isoxicam is combined with Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateIsoxicam may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinIsoxicam may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIsoxicam may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIsoxicam may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Isoxicam is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Isoxicam is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Delapril.Investigational
DesipramineIsoxicam may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinIsoxicam may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of gastrointestinal irritation can be increased when Dexamethasone is combined with Isoxicam.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Isoxicam.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Isoxicam.Experimental
DextranIsoxicam may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinIsoxicam may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Isoxicam is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Isoxicam.Approved, Vet Approved
DicoumarolIsoxicam may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Isoxicam is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Isoxicam.Approved
DihydrostreptomycinIsoxicam may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Isoxicam.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Isoxicam.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Isoxicam.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Isoxicam.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Isoxicam.Approved
DrospirenoneIsoxicam may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Isoxicam is combined with E-6201.Investigational
Edetic AcidIsoxicam may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIsoxicam may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Isoxicam.Approved, Investigational
EnalaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Isoxicam is combined with Enalaprilat.Approved
EnoxacinIsoxicam may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinIsoxicam may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Isoxicam.Experimental
EpanololIsoxicam may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Isoxicam is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Isoxicam.Experimental
EplerenoneIsoxicam may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Isoxicam.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Isoxicam.Approved
EquileninThe risk or severity of adverse effects can be increased when Isoxicam is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Equilin.Approved
EsatenololIsoxicam may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololIsoxicam may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Isoxicam.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ethenzamide.Experimental
Ethyl biscoumacetateIsoxicam may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Isoxicam.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Isoxicam.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Isoxicam.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Isoxicam.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Feprazone.Experimental
Ferulic acidIsoxicam may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Isoxicam.Approved, Investigational
FleroxacinIsoxicam may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Isoxicam.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fludrocortisone.Approved, Investigational
FluindioneIsoxicam may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineIsoxicam may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Isoxicam.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of gastrointestinal irritation can be increased when Fluticasone propionate is combined with Isoxicam.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Isoxicam.Approved, Nutraceutical, Vet Approved
FondaparinuxIsoxicam may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Isoxicam.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Fosinopril.Approved
FramycetinIsoxicam may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Isoxicam.Approved, Vet Approved
GabexateIsoxicam may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinIsoxicam may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinIsoxicam may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Isoxicam.Approved, Withdrawn
GemifloxacinIsoxicam may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinIsoxicam may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinIsoxicam may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AIsoxicam may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ginseng.Approved, Investigational, Nutraceutical
GlipizideThe protein binding of Glipizide can be decreased when combined with Isoxicam.Approved, Investigational
GlyburideThe protein binding of Glyburide can be decreased when combined with Isoxicam.Approved
GrepafloxacinIsoxicam may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Isoxicam is combined with Guacetisal.Experimental
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Isoxicam.Approved, Investigational
HalcinonideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Isoxicam is combined with HE3286.Investigational
HeparinIsoxicam may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Higenamine.Investigational
HydralazineIsoxicam may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Isoxicam.Approved, Vet Approved
HydrocortisoneThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone is combined with Isoxicam.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone acetate is combined with Isoxicam.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of gastrointestinal irritation can be increased when Hydrocortisone butyrate is combined with Isoxicam.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Isoxicam.Approved, Investigational
Hygromycin BIsoxicam may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Isoxicam.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Isoxicam.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Isoxicam is combined with Icosapent.Approved, Nutraceutical
IdraparinuxIsoxicam may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Isoxicam.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Isoxicam.Approved
IndenololIsoxicam may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Indoprofen.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Isoxicam.Approved, Investigational
IsepamicinIsoxicam may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Isoxicam.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Isoxicam is combined with Istaroxime.Investigational
KanamycinIsoxicam may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Isoxicam.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Isoxicam.Approved
LabetalolIsoxicam may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Isoxicam.Approved, Investigational
LandiololIsoxicam may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Isoxicam.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Isoxicam.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Isoxicam.Approved, Investigational
LepirudinIsoxicam may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Isoxicam.Approved, Investigational
LetaxabanIsoxicam may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololIsoxicam may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololIsoxicam may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinIsoxicam may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Isoxicam.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Isoxicam.Experimental
LomefloxacinIsoxicam may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Isoxicam.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Isoxicam.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Isoxicam.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Magnesium salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Isoxicam.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Isoxicam.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Isoxicam is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mefenamic acid.Approved
MelagatranIsoxicam may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Meloxicam.Approved, Vet Approved
MepindololIsoxicam may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Isoxicam.Approved, Investigational, Withdrawn
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Isoxicam.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Isoxicam.Approved
MethylprednisoloneThe risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Isoxicam.Approved, Vet Approved
MetipranololIsoxicam may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Isoxicam.Approved
MetoprololIsoxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Isoxicam.Investigational, Withdrawn
MicronomicinIsoxicam may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Isoxicam.Approved, Experimental
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Isoxicam.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Isoxicam.Approved
MizoribineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Isoxicam.Approved
MoxifloxacinIsoxicam may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Isoxicam.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Isoxicam.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nabumetone.Approved
NadololIsoxicam may decrease the antihypertensive activities of Nadolol.Approved
NadroparinIsoxicam may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatIsoxicam may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Isoxicam.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Isoxicam.Investigational
Nalidixic AcidIsoxicam may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Isoxicam.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Isoxicam is combined with NCX 1022.Investigational
NeamineIsoxicam may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololIsoxicam may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinIsoxicam may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Isoxicam is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nepafenac.Approved, Investigational
NetilmicinIsoxicam may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Isoxicam.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Niflumic Acid.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Isoxicam.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Isoxicam.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Isoxicam.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Isoxicam.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Isoxicam.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Isoxicam.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Nitroaspirin.Investigational
NorfloxacinIsoxicam may increase the neuroexcitatory activities of Norfloxacin.Approved
OfloxacinIsoxicam may increase the neuroexcitatory activities of Ofloxacin.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Isoxicam.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Isoxicam.Approved
OlsalazineIsoxicam may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Isoxicam is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Isoxicam is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Orgotein.Vet Approved
OtamixabanIsoxicam may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Oxaprozin.Approved
Oxolinic acidIsoxicam may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololIsoxicam may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Isoxicam.Approved, Withdrawn
PalmidrolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Parecoxib.Approved
ParomomycinThe risk or severity of nephrotoxicity can be increased when Isoxicam is combined with Paromomycin.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Parthenolide.Approved, Investigational
PazufloxacinIsoxicam may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinIsoxicam may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololIsoxicam may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateIsoxicam may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateIsoxicam may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Perindopril.Approved
PhenindioneIsoxicam may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonIsoxicam may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Isoxicam.Approved, Investigational
PindololIsoxicam may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidIsoxicam may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Isoxicam.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Isoxicam.Approved, Investigational
Piromidic acidIsoxicam may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorIsoxicam may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinIsoxicam may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Isoxicam.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pomalidomide.Approved
Potassium CitrateIsoxicam may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololIsoxicam may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Isoxicam.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of gastrointestinal irritation can be increased when Prednisolone is combined with Isoxicam.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Isoxicam can be increased when it is combined with Probenecid.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Propacetamol.Approved, Investigational
PropafenoneIsoxicam may decrease the antihypertensive activities of Propafenone.Approved
PropranololIsoxicam may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Isoxicam.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Isoxicam.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Isoxicam.Vet Approved
Protein CIsoxicam may increase the anticoagulant activities of Protein C.Approved
Protein S humanIsoxicam may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIsoxicam may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinIsoxicam may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Isoxicam.Investigational
PuromycinIsoxicam may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Isoxicam.Approved
RamiprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinIsoxicam may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinIsoxicam may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Risedronate.Approved, Investigational
RivaroxabanIsoxicam may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinIsoxicam may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinIsoxicam may increase the neuroexcitatory activities of Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Isoxicam.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Isoxicam.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Isoxicam.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Isoxicam.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Isoxicam.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Isoxicam.Approved, Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Isoxicam is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Isoxicam.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Isoxicam is combined with Serrapeptase.Investigational
SisomicinIsoxicam may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinIsoxicam may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateThe risk or severity of bleeding and hemorrhage can be increased when Isoxicam is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Isoxicam.Approved
SotalolIsoxicam may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinIsoxicam may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Isoxicam.Investigational
StreptomycinIsoxicam may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Isoxicam.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Isoxicam.Approved, Investigational
SulodexideIsoxicam may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Isoxicam.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Isoxicam is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Suxibuzone.Experimental
TacrolimusIsoxicam may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Isoxicam.Approved
TalinololIsoxicam may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Isoxicam.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Isoxicam.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Isoxicam.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Isoxicam.Approved, Investigational
TemafloxacinIsoxicam may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tepoxalin.Vet Approved
TerbutalineIsoxicam may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Isoxicam.Approved
TertatololIsoxicam may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Isoxicam.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololIsoxicam may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tixocortol.Approved, Withdrawn
TobramycinIsoxicam may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Isoxicam.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Trandolapril.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Isoxicam.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Isoxicam.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Isoxicam is combined with Triamcinolone.Approved, Vet Approved
TriamtereneIsoxicam may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Isoxicam.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Isoxicam is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Isoxicam is combined with Trolamine salicylate.Approved
TrovafloxacinIsoxicam may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinIsoxicam may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Isoxicam is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Isoxicam.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Isoxicam is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Isoxicam.Approved, Investigational
VancomycinIsoxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
WarfarinIsoxicam may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIsoxicam may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Isoxicam.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Isoxicam.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Isoxicam is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Isoxicam is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Isoxicam.Withdrawn
Food Interactions
Not Available

References

General References
  1. Fenner H: Comparative biochemical pharmacology of the oxicams. Scand J Rheumatol Suppl. 1987;65:97-101. [PubMed:3500509]
  2. DiPasquale G, Rassaert C, Richter R, Welaj P, Gingold J, Singer R: The anti=inflammatory properties of isoxicam (4-hydroxy-2methyl-N-(5-methyl-3isoxolyl-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide). Agents Actions. 1975 Aug;5(3):256-63. [PubMed:1236641]
  3. Evaluation of the Characteristics of Safety Withdrawal of Prescription Drugs from Worldwide Pharmaceutical Markets-1960 to 1999 [Link]
External Links
KEGG Drug
D04639
PubChem Compound
54677972
PubChem Substance
310264909
ChemSpider
10442695
ChEBI
76163
ChEMBL
CHEMBL53292
PharmGKB
PA166049183
HET
ICD
Wikipedia
Isoxicam
PDB Entries
4m10

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.336 mg/mLALOGPS
logP0.6ALOGPS
logP-0.085ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)4.46ChemAxon
pKa (Strongest Basic)-0.97ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area108.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity94.9 m3·mol-1ChemAxon
Polarizability32.24 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0hi2-4920000000-6d8f0aecb48174d3dfd1

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzothiazines. These are organic compounds containing a benzene fused to a thiazine ring (a six-membered ring with four carbon atoms, one nitrogen atom and one sulfur atom).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzothiazines
Sub Class
Not Available
Direct Parent
Benzothiazines
Alternative Parents
Alpha amino acids and derivatives / Organosulfonamides / Benzenoids / 1,2-thiazines / Vinylogous acids / Isoxazoles / Heteroaromatic compounds / N-acylimines / Oxacyclic compounds / Azacyclic compounds
show 4 more
Substituents
Alpha-amino acid or derivatives / Benzothiazine / Ortho-thiazine / Organosulfonic acid amide / Benzenoid / Azole / Isoxazole / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Vinylogous acid
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid amide, isoxazoles, benzothiazine (CHEBI:76163)

Drug created on May 26, 2014 16:17 / Updated on August 02, 2018 06:11